Anti cd16 pc7

Manufactured by Beckman Coulter

Sourced in Italy, United States

Anti-CD16 PC7 is a fluorochrome-conjugated antibody that binds to the CD16 antigen, a low-affinity Fc receptor expressed on natural killer cells, monocytes, and a subset of T cells. This product is intended for use in flow cytometry applications to identify and enumerate CD16-positive cell populations.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using anti cd16 pc7

Flow Cytometric Analysis of Hematopoietic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometer analysis was performed on whole BM samples, using 50 μl of whole blood/tube. Briefly, samples were incubated with specific antibodies (20′ at 4°C in the dark) and then subjected to erythrocytes lysis using BD FACS lysis (BD Biosciences, Milan, Italy) by incubating 15′ at RT in the dark. Cells were washed with PBS 0.5% BSA, suspended in PBS 0.5% BSA and run on Gallios cytometer (Beckman Coulter, Cassina dei Pecchi, Italy), acquiring at least 10⁴ events. Data were analyzed using Kaluza software (Beckman Coulter). The antibodies used were: anti-CD45 PC5 (Beckman Coulter), anti-CD35 FITC (Immunotools, Friesoythe, Germany), anti-CD44 PE (Immunotools), anti-CD117 APC (Miltenyi Biotec, Calderara di Reno, BO, Italy), anti-CD16 PC7 and anti-CD14 FITC (Beckman Coulter), following manufacturer's protocol. PB from 11 NB patients and 10 controls were analyzed for monocytes and granulocytes, whereas PB from 15 NB patients and 10 controls were analyzed for stage II and III erythroblasts.

Morandi F., Barco S., Stigliani S., Croce M., Persico L., Lagazio C., Scuderi F., Belli M.L., Montera M., Cangemi G., Pozzi S., Rigo V., Scaruffi P., Amoroso L., Erminio G., Pistoia V., Ferrini S, & Corrias M.V. (2017). Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget, 8(32), 53194-53209.

+ Open protocol

+ Expand

Neutrophil CD16 Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

All peripheral whole blood samples were taken in EDTA anticoagulated tube and stored at room temperature until flow cytometric testing. Flow cytometric analyses were performed 1–3 h after blood sampling. After mixing well, 100-μL aliquots of blood were incubated for 15 min in the dark at room temperature with ready-to-use monoclonal antibodies (anti-CD16PC7, anti-CD14PE, corresponding mouse isotype control) all purchased from Beckman Coulter (USA). Lyse/no wash procedure was performed using the automated TQ-Prep Workstation and Immunoprep Reagent system (Beckman Coulter). A minimum of 100,000 events for each sample were collected on a Cytomics FC500 flow cytometer and analyzed using CXP software (Beckman Coulter). Relative measurement of CD16 expression was obtained by determining the mean fluorescence intensity (MFI) of neutrophils.
Initially neutrophils were labeled as a distinct population based on side scatter/CD14 dot-plot analysis (Fig. 1A and C), after which CD16 expression (mono-parametric histogram Fig. 1B and D) was also measured as MFI relative to the entire neutrophil population [16 (link)].

Dimitrov E., Halacheva K., Minkov G., Enchev E, & Yovtchev Y. (2024). Better chance of survival is associated with higher neutrophil CD16 expression in patients with complicated intra-abdominal infections. European Journal of Microbiology & Immunology, 14(1), 37-43.

+ Open protocol

+ Expand

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Isolated PBMCs from three different donors were characterized using a CytoDiff flow cytometric system (Navios). Brifely, PBMCs were kept in PBS with 0.1% HSA and differential count of leukocytes was performed after staining with the following antibodies (all from BeckmanCoulter): anti-CD2-APC-AF750 (#B01681), anti-CD14-FITC (#B36297), anti-CD16-PC7 (#6,607,118), anti-CD19-PC5.5 (#B49211), anti-CD34-ECD (#B49202), anti-CD45-KO (#B36294), anti-CD6-PC7 (#A21692), and anti-CD294-PE (#A07413).

Selvin T., Berglund M., Lenhammar L., Jarvius M., Nygren P., Fryknäs M., Larsson R, & Andersson C.R. (2023). Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death. BMC Cancer, 23, 164.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!